The PennZone

LOS ALTOS, Calif. - PennZone -- QView Medical, a breast cancer detection pioneer and maker of the FDA-approved artificial intelligence (AI) software system for breast cancer screening, and GE Healthcare today announced that QView's QVCAD software can be launched on GE Healthcare's Invenia™ ABUS 2.0 (Automated Breast Ultrasound), which has an open platform technology that allows the integration of third-party AI tools for the optimization of the reading workflow.

Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. The powerful AI Assistant leverages intelligent algorithms to assist in detecting breast lesions, helping physicians increase their reading speed with confidence.

Following years of development, QVCAD, which was previously connected to the Invenia ABUS 2.0 through an external PC and server, is now allowing clinicians to access the software through the Invenia ABUS Viewer, streamlining clinical workflow with reducing reading time by up to 33%¹, while improving clinical outcomes with experience up to 93% sensitivity for lesion detection².

Mammography misses one third of cancers in dense breasts³, and while supplemental screening finds more cancers, it requires reasonable callback and biopsy rates⁴.  Dense breasts increase cancer risk by 4-6 times⁵, affecting more than 40 percent of women³. Early cancer detection is critical to increased survival rates and improved patient care and can reduce the cost of care⁶.

More on The PennZone

• Platinum Plumbing Launches First Veteran Hot Water Heater Giveaway to Honor Local Heroes
• Cuts Costs & Boosts Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles
• Inframark Expands Its Specialized Automation and Intelligence Capabilities, Adds Dmytryka Jacobs Engineers
• Sustainable Santa Returns to Old Sacramento
• Upcoming Launch of Retail Crypto Cloud Mining Platform with Daily Rewards in a Transparent Revenue-Share Model: iMD Companies, Inc. Stock Symbol: ICBU

"ABUS combined with QVCAD provides the next crucial step in supplemental breast screening for women with dense breasts," said Bob Wang, Chairman, and CEO of QView Medical.

Brian McEathron, Vice President, General Imaging Ultrasound at GE Healthcare, said, "Our goal is to support clinicians by enabling the timely, accurate diagnosis and treatment of cancer in dense breasts.  The integration of QVCAD into the ABUS reading process is a breakthrough for streamlining workflow and enhancing clinical confidence.  Identifying breast cancer at the earliest possible stage has important prognostic implications:  a greater number of available treatment options, increased survival rates and an improved quality of life."

QView supports the #AMIDENSE public health effort to raise awareness of breast density as a major risk factor.

About QView Medical, Inc.
QView Medical develops and sells AI image-analysis systems for the reading of 3D Automated Breast Ultrasound Systems (ABUS) The QView team has been the leader AI technologies for over twenty-five years including the development of R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS and QView AI/QVCAD.  QView is located in Los Altos, California.  Visit our website www.qviewmedical.com for more information.

More on The PennZone

• BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers
• CRH Healthcare Opens 100th Urgent Care Clinic with Second Peachtree Immediate Care Location in Covington
• COHN Named Colorado State-Approved Vendor for Advertising & Marketing Services
• The Kryder Law Group, LLC Report Reveals Commercial Air Travel Is Safer Than You Think
• RTC Communications Preliminarily Awarded $3.1 Million Federal BEAD Grant to Expand Fiber Broadband in Southern Indiana

--

1. Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women With Dense Breast Tissue (Yulei Jiang). Read More: https://www.ajronline.org/doi/10.2214/AJR.18.19516
2. Performance and Reading Time of Automated Breast US with or without Computer-aided Detection. Read More: https://pubs.rsna.org/doi/10.1148/radiol.2019181816
3. Pisano et al. Diagnostic Performance of Digital versus Film Mammography
4. Mandelson et al. Journal Natl Cancer Inst 2000; 92:1081–1087 for Breast –Cancer Screening. NEJM 2005; 353:1773
5. Boyd, et al, NEJM Jan 2007
6. Blumen, et al. Comparison of treatment costs for breast cancer by tumor stage and type of service